Teijin Pharma Limited, a medical and pharmaceutical subsidiary of Japan’s Teijin Limited—a group worth about $2.5 billion and active in fields such as synthetic fibers, films and plastics, home health care, trading and retail, and IT products—is expanding its global reach in pharmaceuticals and home medical care through the acquisition of Braden Partners L.P.
By April 1, 2009, the start of Teijin’s fiscal year, Braden Partners, a U.S. provider of home oxygen and respiratory medications, equipment and services, will begin doing business under the management of Teijin Pharma, a leading Asian provider of medical devices for home use. Braden Partners, also known as Pacific Pulmonary Services, operates more than 100 patient care centers throughout the western U.S. and reported revenue of $133 million in 2007. Teijin Pharma is utilizing this business venture to enhance its presence in the U.S. through in-licensing and out-licensing products, co-developments and in-house R&D, focusing on respiratory, bone/joint and cardiovascular/metabolic issues. Teijin also offers home oxygen therapy, which, according to the company, has a top market share in Japan.
The acquisition will strengthen Teijin’s presence in the U.S. under an ongoing plan for global expansion, which started in January 2008 with the acquisition of New York-based Associated Healthcare Systems, Inc. Teijin is also considering other acquisitions in order to enter U.S. regional markets where neither AHS nor Braden Partners operates. In addition, the company plans to expand further into Asian and European markets. No word has been given yet as to whether Teijin plans to release more cosmetically-focused medical devices for home use in the near future.